FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin
Назад в Научную Библиотеку

Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin

November 20, 2026
Share
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья является AI-опороченной сводкой последнего опубликованного новости или клинического испытания. Она предназначена для быстрого, доступного обзора для сообщества исследований Peptide. Для полной точности всегда обращайтесь к исходному источнику, указанному ниже.

Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin

A new clinical trial is set to explore the potential benefits of semaglutide, a GLP-1 receptor agonist, as an intervention for managing hypothalamic obesity in children and adolescents aged 12 to 17 years who have undergone treatment for craniopharyngioma. The study, titled "SEMAFORCRANIO," is scheduled to begin recruitment soon at the University Hospital of Angers.

Craniopharyngiomas are rare brain tumors that develop near the pituitary gland and can cause severe complications due to their location in the brain. One of the most significant long-term issues faced by patients with craniopharyngioma is hypothalamic obesity, which often results from damage to the hypothalamus during tumor removal or radiation therapy. This condition leads to rapid weight gain that is difficult to manage through conventional means.

The SEMAFORECRANIO trial aims to evaluate whether semaglutide can help mitigate this severe side effect by targeting appetite regulation and metabolism in young patients who have experienced hypothalamic damage from craniopharyngioma treatment. Semaglutide, marketed under the brand name Wegovy for weight management in adults, has shown promise in clinical settings for its ability to reduce food intake and promote satiety.

Background

Craniopharyngiomas are rare tumors that typically occur during childhood or adolescence but can also develop later in life. These benign tumors often require surgical intervention followed by radiation therapy to prevent recurrence. However, the treatment can lead to significant damage to surrounding brain tissue, including the hypothalamus, which regulates hunger and metabolism.

Hypothalamic obesity is a serious complication that affects many patients who have undergone treatment for craniopharyngioma. This condition can result in rapid weight gain and severe metabolic issues, significantly impacting quality of life and long-term health outcomes. Current treatments are limited, making the development of new therapeutic options critical.

Key Details

The SEMAFORECRANIO trial is a multicenter, double-blind, parallel, randomized controlled study designed to assess the efficacy of semaglutide in managing hypothalamic obesity in children and adolescents aged 12 to 17 years. The trial will compare weekly injections of semaglutide with placebo over an extended period.

Participants will be randomly assigned to receive either semaglutide or a placebo, with neither patients nor researchers aware which treatment is being administered. This design ensures unbiased evaluation of the drug's effectiveness and safety in this specific patient population. The study aims to recruit 120 participants across multiple centers, providing robust data on the potential benefits and risks associated with semaglutide use.

Key Takeaways

  • Semaglutide Shows Promise: Early research suggests that semaglutide may help manage hypothalamic obesity in patients who have undergone treatment for craniopharyngioma.
  • Multicenter Collaboration: The trial involves multiple centers, ensuring a broad and diverse participant pool to validate findings across different settings.
  • Placebo-Controlled Design: A placebo-controlled study design will provide clear evidence of semaglutide's efficacy compared to no intervention.
  • Long-Term Follow-Up: Comprehensive follow-up assessments are planned to evaluate the long-term effects of semaglutide on weight management and metabolic health.

What This Means

The SEMAFORECRANIO trial represents a significant step forward in addressing one of the most challenging complications associated with craniopharyngioma treatment. If successful, this research could pave the way for new therapeutic options that improve quality of life and long-term outcomes for young patients dealing with hypothalamic obesity.

For the peptide community, this study highlights the potential of GLP-1 receptor agonists like semaglutide in managing severe metabolic disorders beyond traditional weight management. The findings from SEMAFORECRANIO could also inform future research into other applications of peptide therapy and contribute to a deeper understanding of hypothalamic function.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

Примечание Редактора

Этот анализ был сгенерирован с использованием инструментов AI и проверен редакционной командой Peptide Contacts. Хотя мы стремимся к точности, содержание, сгенерированное AI, может содержать ошибки или пропуски. Мы призываем читателей проверить исходный источник полные детали, методология и данные.

Peptide Contacts предоставляет сводки научных исследований для информационных целей только. Это содержание не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.

Comments

Sign in to join the discussion

Эта статья была сгенерирована с использованием AI и может содержать неточности. Она предоставляется для информационных целей только и не является медицинским советом. Всегда проверяйте информацию в исходном источнике и консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.